Recap: Amarin Q2 Earnings
AMRN) rose 2.2% in pre-market trading after the company reported Q2 results.
Earnings per share were up 200.00% over the past year to $0.01, which beat the estimate of ($0.07).
Revenue of $135,317,000 higher by 34.25% from the same period last year, which missed the estimate of $149,480,000.
Earnings guidance hasn’t been issued by the company for now.
Revenue guidance hasn’t been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 04, 2020
View more earnings on AMRN” data-reactid=”25″>View more earnings on AMRN
Time: 07:30 AM
https://www.webcaster4.com/Webcast/Page/2037/35819” data-reactid=”27″>ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2037/35819
Company’s 52-week high was at $26.12
Company’s 52-week low was at $3.95
Price action over last quarter: down 5.72%
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa.
View Article Origin Here